newsfilter
← Latest News
GlobeNewswire·

Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena")), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that the Company is